Aarti Pharmalabs
Aarti Pharmalabs
HealthcareKey Fundamentals
MicrocapPharmaceuticalsHealthcarePrice-based figures as of 13 Oct 2026, 14:44 IST · EPS basis: Consolidated · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,760.00 | 34.91 | 4,22,283 Cr | 5.05 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,236.50 | 83.83 | 2,45,200 Cr | 14.63 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,623.70 | 72.59 | 1,75,871 Cr | 20.91 | 0.82% | 12.16% | 9.06% | 15,391 Cr | 2,156 Cr | |
| ₹1,128.40 | 25.11 | 1,12,558 Cr | 4.15 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹2,043.00 | 100.94 | 1,10,386 Cr | 20.83 | 0.10% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,323.10 | 31.70 | 1,06,888 Cr | 3.10 | 1.00% | 11.21% | 14.88% | 28,786 Cr | 3,356 Cr | |
| ₹1,235.50 | 32.00 | 1,03,125 Cr | 2.71 | 0.67% | 10.87% | 13.94% | 34,555 Cr | 3,184 Cr | |
| ₹2,365.10 | 47.81 | 97,689 Cr | 5.99 | 0.04% | 11.70% | 13.78% | 15,074 Cr | 2,067 Cr | |
| ₹1,678.60 | 26.19 | 96,583 Cr | 2.55 | 0.24% | 9.25% | 13.58% | 35,390 Cr | 3,711 Cr | |
| ₹1,942.20 | 16.05 | 88,815 Cr | 3.96 | 0.92% | 23.79% | 28.42% | 30,017 Cr | 5,552 Cr | |
| Aarti Pharmalabs (this company) | ₹876.40 | 37.28 | 7,947 Cr | 3.74 | 0.41% | 8.22% | 11.00% | 1,995 Cr | 213 Cr |
| Median 11 companies | ₹1,760.00 | 34.91 | 1,06,888 Cr | 4.15 | 0.41% | 12.16% | 14.88% | 28,515 Cr | 3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
v2.0.0
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Weaknesses
3- Stock is trading at 4.04 times its book value
- Company has a low return on equity of 11.9% over last 3 years.
- Promoter holding has decreased over last 3 years: -3.44%
Technical Indicators
Oscillators
Bullish
Overall
Bullish
Moving Averages
Bullish
0 of 1 analyst rates Buy, 1 Hold, 0 Sell.
Updated 13 Oct 2026
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 25% · Jun 2026
AI Analysis — Bull vs Bear
Aarti Pharmalabs Ltd is a healthcare company with a market cap of ₹6,378 Cr trading at a PE of 36.7x. The company is experiencing a significant earnings contraction with TTM profit declining 35% and sales declining 14%, while its 3-year stock CAGR of 25% reflects prior momentum that has reversed sharply with a -22% return over the last year.
- 3-year stock CAGR of 25% indicates strong medium-term wealth creation for earlier investors despite recent correction
- 5-year average ROE of 13% suggests the business has historically generated reasonable returns on shareholder equity
- 3-year average ROE of 12% remains above cost of equity for most Indian companies, indicating underlying business quality
- Market cap of ₹6,378 Cr provides reasonable scale and liquidity for institutional participation
- Dividend yield of 0.21% shows the company maintains a dividend payout policy despite earnings pressure
- The -22% stock decline in the last 1 year may offer a more attractive entry valuation compared to prior highs for contrarian investors
- Operating in the healthcare/pharma sector which benefits from structural domestic and export demand tailwinds in India
- TTM compounded profit growth of -35% indicates severe earnings deterioration in the most recent period
- TTM compounded sales growth of -14% shows meaningful revenue contraction, not just margin compression
- PE ratio of 36.7x is elevated given that earnings are declining, implying the stock is priced for growth that is not materializing
- Last year ROE dropped to 9% from a 3-year average of 12%, showing declining capital efficiency
- Price-to-book of 3.01x is high relative to the low ROE of 11.9% over 3 years, suggesting stretched valuation on asset basis
- 3-year compounded profit growth of -3% indicates earnings stagnation even over a medium-term horizon
- 3-year compounded sales growth of -2% shows the topline has been essentially flat over three years
- Stock has declined 22% over the past year, reflecting sustained negative market sentiment and potential de-rating
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- New Tarapur manufacturing block Jun 30
Aarti Pharmalabs inaugurated a new manufacturing block at Tarapur Unit 5, adding 3600 TPA capacity for Xanthine derivatives, bringing total capacity to 9600 TPA.
TL;DR: Aarti Pharmalabs is executing on capacity expansion with a meaningful 60% increase in Xanthine derivatives capacity at Tarapur. No visible headwinds in recent news flow. The trend is constructive as the company invests in growth, though limited news coverage makes it difficult to assess broader operational performance.
Analyst Forecasts
Analyst consensus here uses a different definition from reported ebitda (they differ 8.8× on periods where both exist), so the forecast is shown on its own rather than joined to the reported line.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 458 | 440 | 449 | 506 | 555 | 458 | 538 | 564 | 386 | 418 | 432 | 583 | 536 |
| Expenses | 373 | 352 | 353 | 388 | 459 | 364 | 409 | 418 | 293 | 344 | 330 | 470 | 400 |
| Operating Profit | 85 | 88 | 96 | 118 | 96 | 94 | 129 | 146 | 93 | 74 | 102 | 113 | 136 |
| OPM % | 19% | 20% | 21% | 23% | 17% | 20% | 24% | 26% | 24% | 18% | 24% | 19% | 25% |
| Other Income | 0 | 1 | 1 | 2 | 2 | 4 | 5 | -2 | 2 | 0 | 2 | 14 | 8 |
| Interest | 4 | 4 | 4 | 5 | 5 | 6 | 10 | 7 | 7 | 11 | 13 | 17 | 13 |
| Depreciation | 17 | 18 | 19 | 19 | 20 | 21 | 23 | 23 | 23 | 25 | 29 | 28 | 30 |
| PBT | 64 | 67 | 74 | 96 | 74 | 72 | 101 | 115 | 65 | 39 | 63 | 82 | 101 |
| Tax % | 26% | 23% | 29% | 32% | 25% | 24% | 26% | 23% | 24% | 28% | 24% | 25% | 25% |
| Net Profit | 47 | 52 | 53 | 65 | 55 | 55 | 74 | 88 | 50 | 28 | 48 | 61 | 76 |
| EPS (₹) | 5.2 | 5.72 | 5.82 | 7.2 | 6.12 | 6.03 | 8.16 | 9.75 | 5.46 | 3.08 | 5.29 | 6.74 | 8.4 |
Profit & Loss
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 0 | 1,200 | 1,945 | 1,853 | 2,115 | 1,819 | 1,969 |
| Expenses | 0 | 993 | 1,603 | 1,467 | 1,649 | 1,450 | 1,543 |
| Operating Profit | 0 | 207 | 342 | 386 | 466 | 369 | 426 |
| OPM % | — | 17% | 18% | 21% | 22% | 20% | 22% |
| Other Income | 0 | 3 | 2 | 5 | 8 | 15 | 23 |
| Interest | 0 | 12 | 21 | 17 | 27 | 47 | 53 |
| Depreciation | 0 | 42 | 63 | 73 | 87 | 104 | 112 |
| PBT | 0 | 155 | 261 | 300 | 361 | 233 | 284 |
| Tax % | — | 21% | 26% | 28% | 24% | 25% | — |
| Net Profit | 0 | 122 | 193 | 217 | 272 | 175 | 213 |
| EPS (₹) | — | — | 21.35 | 23.93 | 30.05 | 19.27 | 23.51 |
| Div. Payout % | — | 0% | 9% | 13% | 17% | 18% | — |
Balance Sheet
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 45 | 45 | 45 | 45 |
| Reserves | 0 | 1,386 | 1,513 | 1,712 | 1,945 | 2,079 |
| Borrowings | 0 | 338 | 215 | 285 | 413 | 754 |
| Other Liabilities | 0 | 315 | 470 | 540 | 499 | 603 |
| Total Liabilities | 0 | 2,040 | 2,244 | 2,582 | 2,902 | 3,482 |
| Fixed Assets | 0 | 782 | 926 | 1,033 | 1,137 | 1,437 |
| CWIP | 0 | 187 | 102 | 137 | 374 | 393 |
| Investments | 0 | 32 | 87 | 107 | 77 | 194 |
| Other Assets | 0 | 1,038 | 1,130 | 1,305 | 1,315 | 1,457 |
| Total Assets | 0 | 2,040 | 2,244 | 2,582 | 2,902 | 3,482 |
Cash Flow
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | 0 | -44 | 250 | 216 | 330 | 262 |
| Investing | 0 | -139 | -158 | -215 | -412 | -431 |
| Financing | 0 | 260 | -163 | 10 | 65 | 171 |
| Net Cash Flow | 0 | 78 | -71 | 12 | -17 | 2 |
| Free Cash Flow | 0 | -185 | 130 | 18 | -114 | -186 |
| CFO/OP | — | -11 | 91 | 71 | 85 | 84 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | — | 115 | 84 | 102 | 99 | 117 |
| Inventory Days | — | 272 | 188 | 230 | 199 | 280 |
| Days Payable | — | 123 | 106 | 135 | 94 | 146 |
| Cash Conversion Cycle | — | 264 | 166 | 197 | 204 | 251 |
| Working Capital Days | — | 111 | 94 | 110 | 105 | 90 |
| ROCE % | — | 19% | 16% | 17% | 17% | 11% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Aarti Pharmalabs insights
68 extracted metrics + investor summaries across FY12–FY27.
Documents
Frequently Asked Questions about Aarti Pharmalabs
What does Aarti Pharmalabs Ltd do?
Where is Aarti Pharmalabs Ltd (AARTIPHARM) listed?
Which sector does Aarti Pharmalabs Ltd belong to?
What is the market capitalisation of Aarti Pharmalabs Ltd?
What is the PE ratio of Aarti Pharmalabs Ltd?
What is the 52-week high and low of Aarti Pharmalabs Ltd?
Does Aarti Pharmalabs Ltd pay dividends?
What is the Return on Equity (ROE) of Aarti Pharmalabs Ltd?
Company Information
Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AARTIPHARM.md for Aarti Pharmalabs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.